速递｜拿下埃诺格鲁肽独家商业化权，辉瑞杀入中国减肥药牌桌

Group 1 - Pfizer has gained a new commercial asset in the Chinese weight loss drug market with the approval of Enoglutide injection by the National Medical Products Administration for long-term weight management in overweight or obese adults [4] - The collaboration between Pfizer and Senwaida allows Pfizer exclusive commercialization rights in mainland China, while Senwaida remains responsible for the product's research, registration, production, and supply [4] - The Phase III results show an average weight reduction of 15.4% after 48 weeks of treatment with Enoglutide, with a placebo-adjusted reduction of 15.1% [5] Group 2 - The significance of this collaboration for Pfizer lies in enhancing its market presence in obesity treatment, particularly in the rapidly growing weight loss drug market in China [5] - Future commercial value will depend on pricing, access, and sales progress [5]